Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Metra Biosystems

This article was originally published in The Gray Sheet

Executive Summary

Raises additional $5.1 mil. of equity financing, bringing the total raised during its third round of financing to $12.1 mil. In January, the firm had announced an initial closing of the round at $7 mil. ("The Gray Sheet" Feb. 7, p. 24). New investors include The Traveler's Companies, New York Life, Spears Benzac Solomon & Farrell, Welch & Forbes, and "investors associated with BEA." The Palo Alto, California firm will use the funds for "continued development and commercialization of comprehensive tests for the identification and treatment of bone and cartilage diseases, including osteoporosis, osteoarthritis, hyperthyroidism, hyperparathyroidism, and Paget's disease"
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002180

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel